Skip to content

HEPION PHARMACEUTICALS, INC.: 10-Q filed 2014-02-05

What HEPION PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-02-05 (fiscal Q2 2014): 12 published measures, 28 facts as tagged in accession 0001104659-14-006638.

This filing

Form
10-Q (quarterly report)
Filed
2014-02-05
Fiscal period
fiscal Q2 2014
Accession
0001104659-14-006638 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HEPION PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-318,827USD
At 2013-06-3086,716USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-31-489,860USD
At 2013-06-30-140,495USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-07-01 to 2013-12-310USD184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-07-01 to 2013-12-31852USD184
2013-05-15 to 2013-12-31852USD231

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-163,275USD92
2013-07-01 to 2013-12-31-343,626USD184
2013-05-15 to 2013-12-31-483,794USD231

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-31498,687USD
At 2013-06-30227,211USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-3155,507USD
At 2013-06-303,617USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-10-01 to 2013-12-319,208USD92
2013-07-01 to 2013-12-3122,846USD184
2013-05-15 to 2013-12-3140,587USD231

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-319,000,000shares
At 2013-06-309,000,000shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-12-3133,562USD
At 2013-06-3040,000USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-168,155USD92
2013-07-01 to 2013-12-31-350,217USD184
2013-05-15 to 2013-12-31-490,712USD231
2013-05-15 to 2013-06-30-140,495USD47

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31154,067USD92
2013-07-01 to 2013-12-31320,780USD184
2013-05-15 to 2013-12-31443,207USD231

Inspect the source

Entity
HEPION PHARMACEUTICALS, INC. / CIK 0001583771
Captured
2026-09-20T09:23:01.444Z
SEC response SHA-256
8713b65a28b6abe1fe9df431214197b2d073688f1082552d43175ea3504e60ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001583771.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))